G-SHOCK Channels the Essence of ‘Fantastic Four' in New Timepiece Collaboration
G-SHOCKhas teamed up withMarvel Studiosto launch a limited-edition collector's set celebratingThe Fantastic Four: First Steps' premiere this month. This collaboration pays tribute to Marvel's original superhero family, comprising Mister Fantastic, Invisible Woman, Human Torch and The Thing.
The collaboration features four distinct timepieces, spanning the GA-700HDS, GA-110HDS, GA-6900HDS and GA-2100HDS, with each model channelling the essence of a team member. The watches are engineered for extreme durability with G-SHOCK's signature shock resistance, 200-meter water resistance, as well as heat and freeze-proof construction. Glow-in-the-dark sci-fi dials and white-and-blue accents evoke the retro-futuristic aesthetic of theFantastic Four universe, while exclusive packaging inspired by the 1960s and collectible pin badge sets offer fans a tangible connection to the film's legacy.
Adding a playful twist, Marvel's beloved robot H.E.R.B.I.E. stars in G-SHOCK's campaign video, putting the watches through cinematic durability tests that highlight their toughness and versatility. The launch will be supported by short-form content across social media, in-store displays and web platforms. Prices range from around £100 – £119 GBP (approx. $136 – $163 USD). For more information, visit the collaboration's dedicated webpagehere.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
38 minutes ago
- UPI
Peptides: performance-boosting, anti-aging drugs or harmful snake oil?
Today over 100 peptide medications are approved, including semaglutide – better known as Ozempic and Wegovy. Photo by Haberdoedas Photography/ Pexels For a growing number of middle-aged men, aging no longer means surrendering to sagging skin, sore joints or slowing metabolism. Instead, it's becoming a science experiment. The new frontier? Injectable peptides -- experimental compounds that promise rapid recovery, fat loss and muscle gains with the ease of a twice-daily to weekly jab. Once confined to elite labs and obscure bodybuilding forums, these amino acid chains are now flooding wellness spaces, social media feeds and online marketplaces. Although they are marketed as "next-generation biohacks" and "research chemicals, "many peptides are not approved for human use and lack basic clinical testing. Still, their popularity is growing -- fueled by testimonials, influencer hype and the seductive promise of turning back time. But beneath the surface of glossy marketing and fitness fantasies lies a far more sobering truth: many of these substances operate in a medical gray zone, with unknown long-term risks, questionable manufacturing standards and, in some cases, life-threatening side-effects. Peptides aren't entirely new to medicine. The first peptide drug -- insulin -- was isolated in 1921 and became commercially available in 1923. Today, more than 100 peptide medications are approved, including semaglutide -- better known as Ozempic and Wegovy. But the compounds now circulating in fitness communities represent a very different category. They're experimental substances that have shown promise in animal studies but have never undergone proper human trials. The 'Wolverine stack' One such compound, first discovered in human gastric juice, that is attracting lots of attention is BPC-157. Early animal studies suggest it may help repair damaged tissue throughout the body. Researchers tested it on mice, rats, rabbits and dogs without finding serious side-effects. The compound appears to support healing of the tendons, teeth and digestive organs, including the stomach, intestines, liver and pancreas. Scientists don't yet fully understand how BPC-157 works, but animal studies suggest it triggers several biological processes essential for healing. The compound appears to help cells move to damaged areas and encourages the growth of new blood vessels, bringing nutrients and oxygen to tissues in need of repair. Another compound gaining attention is TB500. It is a synthetic version of thymosin beta-4, a naturally occurring protein fragment that plays an important role in repairing and regenerating damaged cells and tissues. It also helps protect cells from further harm by reducing inflammation and defending against microbes. The combination of BPC-157 and TB500 has earned the nickname "the Wolverine stack," named after the Marvel superhero famous for his rapid healing. Then there's IGF-1 LR3, a modified version of a natural protein (IGF-1) linked to muscle growth. This synthetic compound was shown to increase muscle mass by 2.5 times in animal studies, though it has never been studied in humans. The limited human research that does exist for these compounds offers inconclusive results. For example, a study showed that over 90% of patients experienced reduced knee pain after BPC-157 injections. However, the study had no control group and several methodological issues, so the results should be viewed with caution. Hidden dangers Even though the early results seem exciting, these experimental compounds can be dangerous. Making them involves special chemicals called coupling agents, which can trigger serious allergic reactions, including anaphylaxis -- a life-threatening condition. The health consequences extend well beyond allergic reactions. Long-term injection of performance-enhancing substances can lead to heart failure that can occur rapidly with little warning, as documented in recent medical case studies of young bodybuilders. Injection-related injuries pose another significant threat. "Compartment syndrome" can develop at injection sites in leg muscles, causing numbness, blood clots and muscle spasms that result in permanent loss of function. In severe cases, skin and underlying tissue can suffer necrosis (tissue death), requiring antibiotics or surgery to treat. More alarming still are reports of users contracting HIV, hepatitis B and C, and serious eye infections from contaminated injections. These compounds don't just target muscles -- they affect the entire body in ways scientists are only beginning to understand. Some interfere with natural insulin production, while others activate biological pathways that healthy cells use for growth and repair. The concern is that these same pathways are exploited by cancer cells. The VEGF pathway, which promotes blood vessel growth, is active in about half of all human cancers, including melanoma and ovarian cancer. Laboratory studies suggest that thymosin beta-4 may play a role in helping colorectal and pancreatic cancers spread. While there's no direct evidence linking compounds like BPC-157 or TB500 to cancer, researchers emphasize that the long-term effects remain unknown because these substances have never undergone proper human trials. The World Anti-Doping Agency has banned these compounds, noting they lack approval from any health regulatory authority and are intended only as research tools. A growing problem Yet, their use appears to be spreading rapidly. A 2014 study found that 8.2% of gym members used performance-enhancing drugs. By 2024, a comprehensive review suggested the figure could be as high as 29%. Perhaps most concerning: only 38% of users recognized the health risks involved. These experimental compounds represent a dangerous gamble with long-term health. Unlike approved drugs, they haven't undergone the rigorous testing required to understand their safety profile in humans. While they may promise enhanced performance and healing, they deliver it at a cost that users may not fully understand until it's too late. The appeal is understandable -- who wouldn't want faster healing and better muscle tone? But the reality is these substances remain experimental for good reason. Until proper human trials are conducted, users are essentially volunteering as test subjects in an uncontrolled experiment with their own bodies. Adam Taylor is a professor of anatomy at Lancaster University. This article is republished from The Conversation under a Creative Commons license. Read the original article. The views and opinions in this commentary are solely those of the author.
Elle
an hour ago
- Elle
Zendaya Offers a Rare Glimpse of Her Engagement Ring While Walking Dogs With Tom Holland
THE RUNDOWN Zendaya and Tom Holland have been busy working on several projects this year, with the couple now beginning production on Spider-Man: Brand New Day. The Marvel film is shooting in Glasgow, but Holland and Zendaya recently enjoyed some downtime in London's Richmond Park. The Sun ran photos of the pair walking their two dogs. Zendaya had on a pink oversize sweater and dark capris, with her hair down in waves. Her east-west engagement ring stood out against the casual look. See the shots here. Holland, meanwhile, wore a burgundy baseball cap embroidered with the name of his nonalcoholic beer company, Bero, along with a light-blue short-sleeve top and gray pants. Zendaya's longtime stylist, Law Roach, recently revealed the couple is holding off on planning their wedding despite getting engaged over six months ago. 'The process hasn't even started yet,' he told E! at the Las Culturistas Culture Awards' red carpet last month. 'Zendaya is working on so many movies. She's now filming the next iteration of Dune [Part Three in Hungary], so she's away doing that. It's so many movies, so we have time. We have a lot of time.' He added that the actress will be 'a secret bride,' as the pair would like to keep their nuptials private. Zendaya has been filming The Odyssey, Euphoria's third season, and Dune: Part Three this spring and summer; she'll now begin work on Spider-Man: Brand New Day as well, where she'll reprise her role as MJ. Holland is shooting Spider-Man and is also in The Odyssey.
Yahoo
an hour ago
- Yahoo
Box Office: ‘Fantastic Four' Craters by 66% in Second Weekend, ‘Naked Gun' Debuts to $17 Million
Marvel's First Family might not save the day after all. 'The Fantastic Four: First Steps' is quickly losing steam in its second weekend, signaling the comic book adventure isn't connecting at the box office beyond the film's core demographic of superhero fans. After a healthy $117.6 million debut, 'The Fantastic Four' suffered a hefty 66% drop in its sophomore outing with $40 million from 4,125 theaters. Heading into the weekend, box office analysts anticipated a decline of 55% to 60% from its opening. (By comparison, 'Superman' dropped by 53% in its second weekend after launching to $125 million earlier in July.) This painful fall is surprising because the Marvel tentpole has the benefit of positive reviews and word-of-mouth, as well as a clear runway in terms of competition. More from Variety 'Together' Stars Dave Franco and Alison Brie Relive Their Off-Screen Wedding: Weed Pens, Pizzeria Mozza and a Party Crasher Liam Neeson Jokes His Death as Qui-Gon Jinn in 'The Phantom Menace' Was 'A Bit Namby-Pamby': 'Please, Hardly a Master Jedi' 'Bad Guys 2' Director on Spoofing Elon Musk's SpaceX and How the Cold Open Was Influenced by 'Skyfall' and 'Mission: Impossible' Although those ticket sales were enough to rank as No. 1 on North American charts, 'The First Steps' endured one of the steeper second-weekend drops for Disney's Marvel Cinematic Universe, better than 'The Marvels' (down 78%) but in the company of February's 'Captain America: Brave New World' (down 68%), 2023's 'Ant Man and the Wasp: Quantumania' (down 70%) and 2022's 'Thor: Love and Thunder' (down 67%). So far, 'Fantastic Four' has generated $198 million domestically and $368 million globally. Luckily for Marvel, whose output has been wildly inconsistent in post-pandemic times, 'The First Steps' is pacing to outgross this year's prior theatrical disappointments of 'Captain America: Brave New World' ($415 million globally) and 'Thunderbolts' ($382 million globally). The final tally for 'Fantastic Four' won't be disastrous, à la 'The Marvels' ($206 million) or 'Thunderbolts,' but it's not yet a return to box office glory for Marvel. However, the MCU should officially regain its box office stride with its next three films — 2026's 'Spider-Man: Brand New Day' and 'Avengers: Doomsday' and 2027's 'Avengers: Secret Wars.' ''Fantastic Four' is not a top-tier Marvel franchise. Never has been,' says analyst Jeff Bock of Exhibitor Relations. 'Remember, this ramps up into 'Avengers.' That's the real payoff.' Three new movies opened nationwide, but none were competing for the same audience as 'Fantastic Four.' Among new releases, Universal and DreamWorks Animation's heist comedy 'The Bad Guys 2' enjoyed the strongest start with $22.8 million from 3,852 venues. That's directly even with the first film, which opened to $23 million in 2022 at a time when cinemas were majorly struggling to recover from COVID and studios were barely releasing any movies. The original film eventually powered to $250 million worldwide. 'The Bad Guys 2,' which cost $80 million and follows a group of reformed criminals who relapse for one final con job, was embraced by audiences with an 'A' grade on CinemaScore exit polls. Overseas, 'The Bad Guys 2' landed with $16.3 million for a global total of $44.5 million. 'This is a good opening for an animation sequel,' says analyst David A. Gross of Franchise Entertainment Research. 'With this kind of business, the movie is doing what it's supposed to do.' At No. 3, Paramount's slapstick comedy 'The Naked Gun' debuted to $17 million from 3,344 theaters, right in line with projections. The film earned another $11.5 million at the international box office, bringing its global tally to $28.5 million. It's a promising start given the dearth of theatrical comedies. Akiva Schaffer of the Lonely Island fame directed the film, which carries a $42 million price tag. Critics and moviegoers dug 'The Naked Gun,' in which Liam Neeson stars as bumbling L.A. detective Frank Drebin Jr. (son of the late Leslie Nielsen's Frank Drebin, his predecessor in the 'Naked Gun' trilogy) alongside Pamela Anderson and Paul Walter Hauser. The movie scored an 'A-' grade on CinemaScore and boasts a 90% average on Rotten Tomatoes, both of which should bode well for the remainder of its theatrical run. 'The Naked Gun' appealed almost squarely to older white men; 62% of initial crowds were male, 50% were above 35 years old and 70% were Caucasian. This weekend's final newcomer, Neon's body-horror nightmare 'Together' landed in sixth place with $6.8 million over the traditional weekend and an encouraging $10.8 million during its first five days of release. Real-life husband and wife Dave Franco and Alison Brie star in 'Together' as a co-dependent couple who become frighteningly close after a mysterious force causes horrific body changes. Audiences gave the film a 'C+' on CinemaScore, though that harsh a grade isn't surprising since they likely left the theater feeling very disturbed. In fact, Neon has been leaning into the on-screen trauma to promote the movie, offering free couples therapy for partners who see 'Together' during opening weekend. Neon shelled out $17 million to buy the movie at Sundance, marking one of the richest deals in the festival's history. 'A lukewarm audience score is typical of these films and generally has little effect on how they play out,' Gross says. 'It's [a] smart horror production that's going to be profitable when it's finished.' Elsewhere at the box office, 'Superman' descended to fourth place with $13.9 million in its fourth weekend of release. The Warner Bros. and DC Studios adaptation has generated $316.2 million domestically and $551.2 million globally to date. Universal's 'Jurassic World Rebirth' rounded out the top five with $8.4 million in its fifth weekend of release. The dinosaur epic, which rebooted the long-running property with Scarlett Johansson, Jonathan Bailey and Mahershala Ali, has grossed $317 million in North America and $766 million globally. Overall, the box office is 9.5% ahead of last year but 23% behind 2019, the last pre-pandemic year, according to Comscore. Summer revenues just hit $3 billion from May through early August, so it's a question of whether this could be the second summer in post-COVID times — the year of 'Barbenheimer' was the first — to cross the $4 billion milestone. 'A solid home stretch of the summer is in the cards,' predicts senior Comscore analyst Paul Dergarabedian. 'The $4 billion benchmark is still about a $1 billion away, which is no cake walk but potentially in play.' Solve the daily Crossword
